REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedClinical Trial

[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].

Gusev E I, Martynov M Yu, Kostenko E V, Petrova L V, Bobyreva S N
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2018DOI: 10.17116/jnevro20181183261-68

Citations

0

Subjects

Non-Human

Study Context

This clinical trial followed a structured protocol to evaluate outcomes. The controlled methodology adds credibility to the reported results.

Citation

Gusev E I, Martynov M Yu, Kostenko E V et al.. (2018). [The efficacy of semax in the tretament of patients at different stages of ischemic stroke].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. https://doi.org/10.17116/jnevro20181183261-68

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.